H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Amicus (NASDAQ:FOLD) Therapeutics on Tuesday, setting a price target of $20, which is approximately 79.53% above the present share price of $11.14.
Chattopadhyay expects Amicus Therapeutics to post earnings per share (EPS) of -$0.35 for the second quarter of 2020.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Amicus, with an average price target of $17.3.
The analysts price targets range from a high of $20 to a low of $12.5.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $60.53 million and a net profit of -$77.13 million. The company's market cap is $2.87 billion.
According to TipRanks.com, H.C. Wainwright analyst Debjit Chattopadhyay is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 15.6% and a 52.50% success rate.
Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.